TargetGene is a recognized innovative gene-editing pioneer with our proprietary, best-in-class TGEE platform. TGEE is a super-precise dual-guide-based editing system that is as versatile as CRISPR but without the latter's off-target safety concerns. In-vivo genetic manipulations are exceedingly susceptible to off-target risks. Thus, we are leveraging TGEE's advantages to rewire cell transcriptomes to develop safe and effective cell therapies for cancer, immune-related-, and genetic disorders.
TargetGene is seeking partners participating in development of novel cell and gene-therapies that can benefit from our safer gene-editing platform, including Clinicians, Academia, Delivery-platform developers, Pharma, Patient advocacy organizations and CDMOs.